Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 10, 2025 • 9:31 PM ET

Date/Time Source News Release
07/10/2023 04:01 PM EDT GlobeNewswire Arbutus Appoints Two New Executives
01/06/2023 07:01 AM EST GlobeNewswire Nabriva Therapeutics Provides Corporate Update
11/28/2022 07:01 AM EST GlobeNewswire Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
11/10/2022 04:01 PM EST GlobeNewswire Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate Update
11/07/2022 07:01 AM EST GlobeNewswire Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022
09/15/2022 07:01 AM EDT GlobeNewswire Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
09/06/2022 07:01 AM EDT GlobeNewswire Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
08/11/2022 07:01 AM EDT GlobeNewswire Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
08/03/2022 04:01 PM EDT GlobeNewswire Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
07/20/2022 04:05 PM EDT GlobeNewswire Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022
Page

Additional News

As of June 10, 2025 • 9:31 PM ET

Date/Time Source News Release
07/11/2023 03:46 AM EDT SeekingAlpha Arbutus Biopharma appoints Karen Sims as chief medical officer
05/19/2023 08:20 AM EDT SeekingAlpha BE, OUST and RIGL are among pre market gainers
03/27/2023 10:47 AM EDT SeekingAlpha NBRV, JNCE and ALIM among healthcare movers
02/06/2023 08:21 AM EST SeekingAlpha Merck, Nabriva terminate distribution agreement for antibacterial
11/29/2022 12:57 PM EST Zacks Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
11/13/2022 07:40 PM EST SeekingAlpha Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript
11/10/2022 04:02 PM EST SeekingAlpha Nabriva Therapeutics GAAP EPS of -$4.21 misses by $0.18, revenue of $9.15M misses by $1.53M
09/16/2022 12:39 PM EDT InvestorPlace Rigetti (RGTI) Stock Pops on New Quantum Computing Partners
09/16/2022 11:52 AM EDT InvestorPlace Why Is Esports Entertainment (GMBL) Stock Down 45% Today?
09/16/2022 11:30 AM EDT InvestorPlace What Is Going on With Nabriva Therapeutics (NBRV) Stock Today?
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.